Screener
McKesson MCK Prescription Technology Solutions — Asset impairments and accelerated depreciation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept mck:AssetImpairmentChargesIncludingAcceleratedDepreciation.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | Three Months Ended June 30, 2026 / North American Pharmaceutical (1) | Three Months Ended June 30, 2026 / Prescription Technology Solutions (1) | Three Months Ended June 30, 2026 / Medical-Surgical Solutions (1) | Three Months Ended June 30, 2026 / Corporate (1) | Total |
|---|---|---|---|---|---|
| Severance and employee-related costs, net | — | $11 | $14 | $7 | $32 |
| Exit and other-related costs (2) | 1 | 10 | 9 | 37 | 57 |
| Asset impairments and accelerated depreciation | 1 | 40 | — | 6 | 47 |
| Total | $2 | $61 | $23 | $50 | $136 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's prescription technology solutions — asset impairments and accelerated depreciation?
- McKesson (MCK) reported prescription technology solutions — asset impairments and accelerated depreciation of $40M in Q2 2026.
- What is the long-term trend for McKesson's prescription technology solutions — asset impairments and accelerated depreciation?
- Over 3 years (2022 to 2025), McKesson's prescription technology solutions — asset impairments and accelerated depreciation has grown at a -23.4% compound annual growth rate (CAGR), from $20M to $9M.
- What does prescription technology solutions — asset impairments and accelerated depreciation mean?
- Reflects non-cash charges resulting from the write-down of long-lived assets or the accelerated depreciation of assets due to changes in their expected useful life within the Prescription Technology Solutions segment. This often signals a strategic pivot or the obsolescence of technology platforms.
Ask your AI about McKesson's prescription technology solutions — asset impairments and accelerated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude